Tevogen.AI Boosts PredicTcell™ Accuracy, Expands AI Infrastructure — Tevogen Bio Holdings Inc.

Event summary

Tevogen.AI improved PredicTcell™ beta recall from 87% to 92% and precision from 40% to 48%.
The company's proprietary database now includes 655 million peptide sequences from 24 million proteins.
Tevogen.AI operates three production AI agents monitoring 14 active peptide candidates and integrating wet lab results.
The current model is trained on 1.8 million data points, 20x more robust than the initial version.

The big picture

Tevogen.AI's advancements address a critical bottleneck in drug development: identifying viable biological targets before costly clinical trials. The company's continuous learning loop between AI predictions and biological validation positions it to reduce development costs and increase success rates in immunotherapy. This strategic focus on precision medicine aligns with broader industry trends toward AI-driven drug discovery and personalized treatment approaches.

What we're watching

Partnership Strategy: How Tevogen.AI's improved accuracy will attract pharmaceutical partnerships for peptide candidate development.
Execution Risk: Whether the company can sustain rapid scale and learning acceleration in its AI models.
Market Differentiation: The pace at which Tevogen.AI can establish itself as a leader in reducing trial-and-error in immunotherapy design.